Movement Alert|SELLAS Life Sciences Group Inc. Intraday Rise 212.77% in Regular Trading, Phase 3 Cancer Vaccine Trial Met Primary Endpoint

Market Focus11-17 22:32

On November 17, SELLAS Life Sciences Group Inc. rose 212.77% in Regular Trading, trading at $23.1703 per share, with turnover of $732 million.

The move followed the company’s announcement that galinpepimut-S met the primary endpoint in the Phase 3 REGAL trial in acute myeloid leukemia, showing a statistically significant overall survival benefit.

According to the disclosed trial results, patients receiving the vaccine achieved median overall survival of 24 months versus 14.7 months for the control arm, while the risk of death was reduced by 41%. The company also said the therapy was generally well tolerated with no new safety issues identified. SELLAS Life Sciences Group Inc. plans to meet with the FDA to discuss an accelerated filing strategy and prepare a marketing application submission in the first half of 2027, while additional analyses including secondary endpoints remain ongoing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment